European Pharmaceutical Review

AUGUST 17, 2022

The investigators found that the high burden of chronic and infectious diseases, growing focus on bioavailability enhancement for poorly soluble drugs, and the challenges associated with drug development were the major contributors to the demand for formulation development services globally.

Compounding 96

Compounding Pharmaceutical Companies Pharmaceutical Companies Drug Development 96

pharmaphorum

SEPTEMBER 21, 2022

“Regulators are strongly suggesting companies get patient input and really understand the patient experience. In 2019, ZS Associates carried out a global survey of pharmaceutical companies to get a better idea of patient centricity perceptions and behaviours. And that is driving change.”. The optimism gap’.

Drug Development 98

Drug Development Pharmaceutical Companies Pharmaceutical Companies 98

European Pharmaceutical Review

FEBRUARY 21, 2023

After the substance became legal in the UK in 2018, pharmaceutical companies have faced numerous obstacles to attain a fairer position in the industry. GMP-certified product[s] – [are part of] the foundation of building a truly pharmaceutical cannabis sector.” ” Our approach has always been to work with regulators.

Pharmaceutical Companies 132

Pharmaceutical Companies Pharmaceutical Companies Compounding Drug Development 132

pharmaphorum

SEPTEMBER 20, 2022

The big pharma company is making a $20 million investment in the Israeli startup along with funding that could reach $90 million over the next five years, in a return for options to license CytoReason’s AI platform and disease models. ” He goes on: “That’s exactly what our computational disease models are designed to do.

Drug Development 52

Drug Development Immunity Immunization Pharmaceutical Companies 52

European Pharmaceutical Review

DECEMBER 21, 2022

“As the contribution of costs of organic chemicals used as feedstock to the operating expenditures is small, the pharmaceutical companies can spearhead and guide the transition.” He is currently group leader of the Technology Development and Discovery Group at the Bioprocess Laboratory of the ETH. Ramboll website.

Compounding 97

Compounding Pharmaceutical Manufacturing Pharmaceutical Companies Pharmaceutical Companies 97

pharmaphorum

JUNE 2, 2022

In 1983, the US Congress passed the Orphan Drug Act to encourage more pharmaceutical companies to engage in R&D to develop treatments for rare diseases through the offering of financial incentives. As covered in a previous article , the importance of R&D to develop treatments for rare diseases is high.

Compounding 52

Compounding Pharmaceutical Companies Pharmaceutical Companies Drug Pricing 52

European Pharmaceutical Review

JANUARY 13, 2025

3 Encouragingly, there are many examples of the life sciences sector seeking to embrace sustainable drug development; reconciling the drive for innovation with the need to reduce waste and emissions produced during the R&D process, as well as throughout the product lifecycle. Pulmonary Pharmacology & Therapeutics.

Packaging 52

Packaging Community Pharmacies Documentation Pharmaceutical Companies 52

pharmaphorum

OCTOBER 12, 2022

“We founded Whitelab Genomics after realising the potential to use data, data science, and AI in a more systematic way to develop genomic therapies,” Del Bourgo says. In 2019, Del Bourgo and co-founder Julien Cottineau launched Whitelab Genomics and its AI platform dedicated to supporting the discovery and design of genomic therapies. “We

Drug Development 105

Drug Development Immunity Immunization Vaccines 105

pharmaphorum

APRIL 11, 2022

Delivering value for patients doesn’t start and end in our R&D labs; actions can be implemented across all stages of the drug development lifecycle to encourage and embrace a pro-innovation environment. Between 2016-2019, she was the medical affairs therapeutic area lead in haematology for Janssen Oncology across the EMEA region.

Pharmaceutical Companies 115

Pharmaceutical Companies Pharmaceutical Companies Vaccines Packaging 115

Pharmaceutical Technology

MAY 12, 2023

Speciality pharmaceutical company SERB Pharmaceuticals has acquired exclusive US rights for bentracimab from SFJ Pharmaceuticals. SFJ Pharmaceuticals will lead the ongoing clinical trial of bentracimab. The US FDA granted breakthrough therapy designation to bentracimab in 2019.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Drug Development 52

pharmaphorum

JANUARY 27, 2023

Late last year, pharmaphorum caught up with Dr Karen Mullen, chief medical officer and VP of clinical & medical affairs at global drug development consultancy Boyds. We talk a lot in clinical trials and drug development about benefit,” Dr Mullen said. I still feel that it is very important,” Dr Mullen said. “We’ve

Vaccines 111

Vaccines Pharmaceutical Companies Pharmaceutical Companies Documentation 111

pharmaphorum

SEPTEMBER 9, 2021

Janssen currently has more than 150 partnerships in play , with a view to developing and delivering new products that can advance scientific research and provide value to patients, physicians, and healthcare systems around the world. About the author. The post Preparing for a post-pandemic world appeared first on.

Communication 52

Communication Pharmaceutical Companies Pharmaceutical Companies Hospitals 52

PharmaShots

FEBRUARY 21, 2023

The company is developing PPMX-T002, an anti-cancer drug with an antibody targeting CDH3 connected with a radioisotope yttrium 90 (90Y). Perseus has been discussing the collaborative development of PPMX-T002 with various RI medical drug-developing companies, including PeptiDream and its subsidiary PDRAdhiopharma.

Dosage 56

Dosage Labelling Immunity Immunization 56

Pharmaceutical Technology

NOVEMBER 4, 2022

Goods were largely delivered on time, and at a low cost, benefitting both companies and consumers. According to GlobalData’s Social Media Analytics, supply chains were mentioned on Reddit and Twitter 1,908 times in 2019. As such, few people were focused on them. By 2021, social media mentions of supply chains reached 25,636.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Vaccines Drug Development 52

Putting Patients First Blog

JUNE 30, 2023

have robust suggestions on increasing diversity in clinical trials for sponsors and drug developers. As an organization with a diverse membership of multiple patient advocacy organizations and biotech and pharmaceutical companies, we believe these new changes could lead to confusion and duplicative efforts.

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceutical Companies Drug Development 40

Pharmaceutical Technology

MARCH 22, 2023

According to the GlobalData report Contract Injectable Packaging Trends in the Bio/Pharma Industry , more than half (55%) of FDA drug approvals in 2021 were accounted for by injectables. This was higher than the number of approvals in 2019 and 2020. Several drug development trends are driving injectables demand.

Packaging 52

Packaging Compounding Pharmaceutical Companies Pharmaceutical Companies 52

Drug Patent Watch

DECEMBER 11, 2024

This growth has created a competitive landscape where pharmaceutical companies must carefully evaluate and select the right CDMO partner to ensure the success of their projects. Your Drugs Development Stage The stage of your drug development is a critical factor in selecting a CDMO.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies Communication Drug Development 98

Drug Patent Watch

DECEMBER 18, 2024

This exclusivity is the lifeblood of pharmaceutical innovation, allowing companies to recoup their massive R&D investments and incentivizing further research. According to a 2021 study by the Tufts Center for the Study of Drug Development, the average cost to develop a new drug is a staggering $2.6

Drug Development 98

Drug Development Compounding Dosage Pharmaceutical Companies 98

Pharmaceutical Technology

AUGUST 1, 2022

million direct deaths in 2019 and an additional 4.95 A 2017 article in Health Policy estimates that the cost of developing an antibiotic is around $1.5bn, while according to a 2020 article in Nature, the average revenue generated from an antibiotic’s sale is about $46m a year.

Vaccines 93

Vaccines Pharmaceutical Companies Pharmaceutical Companies Chemotherapy 93